Canada Markets open in 7 hrs 39 mins

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.68+0.16 (+2.45%)
At close: 04:00PM EDT
6.68 0.00 (0.00%)
After hours: 04:19PM EDT

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Senthil Vel SundaramCEO & Director850.2kN/A1978
Dr. Erin Quirk M.D.Pres & Head of R&D662.55kN/A1971
Mr. Seokho Yoon Esq.COO, Gen. Counsel & Sec.609.37kN/A1978
Dr. Weidong Zhong Ph.D.Co-Founder & Exec. OfficerN/AN/A1966
Dr. Mark Joseph VignolaCFO & TreasurerN/AN/A1978
Dr. Jeffrey R. Jasper Ph.D.Sr. VP & Head of ResearchN/AN/AN/A
Ms. Diana ChungSr. VP & Chief Devel. OfficerN/AN/AN/A
Dr. Kerry Russell M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Corporate Governance

Terns Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.